AstraZeneca's silence on CEO wipes out £billions

ReutersNews Published July 14, 2017 0 Plays

Rumble Uncertainty over the future of AstraZeneca Chief Executive Pascal Soriot drove the Anglo-Swedish drugmaker's shares lower again on Friday, taking the cost of two days of silence to more than 3 billion pounds ($3.9 billion). Ciara Lee reports.